ESTIMABL2: No radioiodine at 5 years | Hormone Insight Podcast
What happens at 5 years of follow-up with thyroidectomy without radioiodine in patients with low-risk thyroid cancer?
In patients with low-risk differentiated thyroid cancer, a follow-up strategy without radioiodine was non-inferior to postoperative radioiodine at 5 years.
Randomized trial · Lancet Diabetes Endocrinol 2025
Reference: Leboulleux. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. The Lancet Diabetes & Endocrinology. 2025;13(1):38–46. doi:10.1016/S2213-8587(24)00276-6. PMID:39586309.
Chapters
0:00 Intro
0:38 The trial
3:19 My take
3:50 Outro
Read the structured trial summary at https://hormoneinsight.com
AI narration is used. This podcast is intended for healthcare professionals only. It is educational, not medical advice. Views expressed are the presenter’s own and do not necessarily reflect those of any institution he works with.
Hormone Insight: https://hormoneinsight.com
Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856
Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en
15 Oct 2026
IoN: Skip radioiodine? | Hormone Insight Podcast
After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation?
In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival.
Randomised multicentre non-inferiority trial · The Lancet 2025
Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/
This is a summary of trial findings, not an individual treatment recommendation.
AI-narrated episode. For healthcare professionals; educational only and not medical advice.
Hormone Insight: https://hormoneinsight.com/
Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856
Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en
14 Oct 2026
Rosiglitazone: A heart attack signal? | Hormone Insight Podcast
Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes?
A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death.
Meta-analysis · New England Journal of Medicine 2007
Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
AI-narrated episode. For healthcare professionals; educational only and not medical advice.
Hormone Insight: https://hormoneinsight.com/
Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856
Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
326,562
Score snapshot 15 Sept 2025
Podcast Authority Score: 22 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
9
Social presence
0
YouTube
86
Engagement
0
Contact Hormone Insight
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Hormone Insight?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
